TABLE 1.
Influence of age and SERT genotype on the potency (ED50) and maximal effect (Emax) of DMI to reduce immobility time in the TST
Data are expressed as means ± S.E.M. Values were calculated from data shown in Fig. 1, D–F, and Table 1.
| Age | SERT | ED50 | Emax |
|---|---|---|---|
| mg/kg | %Δ Control | ||
| P21 | +/+ | 7.5*,** | 70.1 ± 5.4* |
| +/− | 17.4** | 68.5 ± 7.0 | |
| −/− | 17.1** | 62.4 ± 8.9** | |
| P28 | +/+ | 23.7* | 57.5 ± 10.6 |
| +/− | 36.3 | 41.3 ± 8.6 | |
| −/− | 45.2*** | 32.3 ± 9.2 | |
| P90 | +/+ | 37.3 | 47.0 ± 6.1 |
| +/− | 29.1 | 47.3 ± 7.7 | |
| −/− | 30.5 | 51.9 ± 9.2 |
Sample sizes per data point were as follows: SERT+/+, n = 21–31 (9–14 males and 10–20 females, pooled); SERT+/−, n = 16–20 (8–10 males and 8–12 females, pooled); and SERT−/−, n = 18–23 (8–10 males and 9–14 females, pooled). For ED50 values, comparisons were made by the F ratio test to compare intercepts. For Emax values, comparisons made by the Tukey post hoc multiple comparisons test after a two-factor ANOVA. Because there were no statistically significant sex differences, data for male and female mice were pooled.
P < 0.05 (difference from SERT genotype–matched P90); **P < 0.05 (difference from SERT genotype–matched P28); ***P < 0.05 (difference from age-matched SERT+/+ group).